Direkt zum Inhalt
Merck

Fortfahren mit

46412

Medroxyprogesteron-17-Acetat

VETRANAL®, analytical standard

Synonym(e):

17α-Acetoxy-6α-methylprogesteron, 17α-Hydroxy-6α-methyl-4-pregnen-3,20-dion-17-acetat, 6α-Methyl-17α-acetoxyprogesteron, 6α-Methyl-17α-hydroxyprogesteron-acetat

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis

Über diesen Artikel

Empirische Formel (Hill-System):
C24H34O4
CAS-Nummer:
Molekulargewicht:
386.52
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
200-757-9
Beilstein/REAXYS Number:
2066112
MDL number:
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


grade

analytical standard

Quality Level

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

206-207 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

InChI key

PSGAAPLEWMOORI-PEINSRQWSA-N

Gene Information

human ... PGR(5241)

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
PHR1589M02500001378001
application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

-

grade

analytical standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

Gene Information

human ... PGR(5241)

Gene Information

human ... PGR(5241)

Gene Information

human ... PGR(5241)

Gene Information

human ... PGR(5241)

product line

VETRANAL®

product line

-

product line

-

product line

-


Still not finding the right product?

Explore all of our products under Medroxyprogesteron-17-Acetat


pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

Aquatic Chronic 4 - Carc. 2

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Jeong-Yeol Park et al.
Obstetrics and gynecology, 121(1), 136-142 (2012-12-25)
To analyze pregnancy outcomes in young women with stage IA, grade 1 endometrioid adenocarcinoma of the uterus after successful fertility-sparing management using progestin. We reviewed the medical records of 141 women with stage IA, grade 1 endometrioid adenocarcinoma of the
JoAnn E Manson et al.
JAMA, 310(13), 1353-1368 (2013-10-03)
Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention
Robert A Wild et al.
Menopause (New York, N.Y.), 20(3), 254-260 (2013-02-26)
Our objective was to determine whether metabolic syndrome (MetS) or its components modified the effect of hormone therapy (HT) on the risk of coronary heart disease (CHD) events in the Women's Health Initiative clinical trials. We performed a nested case-control



Global Trade Item Number

SKUGTIN
46412-250MG04061835560738

Questions

Reviews

No rating value

Active Filters